FOXO4-DRI 10mg is a research-grade senolytic peptide studied for clearing senescent cells. Learn how it works, how it compares, and its legal status.
FOXO4-DRI 10mg is a 10-milligram vial of FOXO4-DRI, a synthetic peptide studied for its ability to push senescent cells into apoptosis. It works by blocking the interaction between FOXO4 and p53, a protein pairing that keeps damaged, non-dividing cells alive when they should be cleared. The 10mg size is a research-grade quantity sold for laboratory work only, and it is not FDA-approved for human use.
What Is FOXO4-DRI 10mg?
FOXO4-DRI is a modified peptide built from a fragment of the natural FOXO4 protein. Chemists added a D-amino acid retro-inverso modification, which makes the molecule more stable and helps it cross into cells. The result is a compound that interferes with a survival signal inside senescent cells.
Senescent cells stop dividing but do not die. They release inflammatory signals into surrounding tissue, a behavior often called the senescence-associated secretory phenotype. Compounds that selectively kill these cells are known as senolytics, and FOXO4-DRI is one of the most frequently cited experimental examples.
A 10mg vial holds lyophilized, or freeze-dried, powder. Because it is a research chemical, it ships without dosing guidance, and suppliers typically state that it is not for human or veterinary use.
How FOXO4-DRI Works on Senescent Cells
In healthy cells, FOXO4 and p53 stay bound together in a way that supports normal function. In senescent cells, that same interaction keeps p53 locked out of the nucleus, blocking the apoptosis pathway that would otherwise clear a damaged cell.
FOXO4-DRI competes with natural FOXO4 for the same binding site on p53. When the peptide wins that competition, p53 is released, moves into the nucleus, and triggers programmed cell death. FOXO4-DRI is designed to kill senescent cells while leaving healthy, dividing cells largely untouched in laboratory and animal models.
Why Selectivity Matters
Older senolytics such as navitoclax can damage platelets and other healthy tissue. Selectivity is the main reason this peptide draws research interest, though a clean profile in mice does not guarantee the same behavior in humans.
Why the 10mg Vial Size Is Common
A 10mg vial is a mid-sized research quantity. It is large enough to support multiple in vitro experiments but small enough to stay affordable for academic labs.
- Usually sold as a sterile-filtered, lyophilized powder.
- Reconstituted in the lab with bacteriostatic water or a compatible buffer.
- Stored at -20°C or colder for long-term stability.
- Purity commonly reported by HPLC at 98% or higher.
Buyers should look for a third-party certificate of analysis. Purity and endotoxin data matter far more than the label on the vial, especially for cell-culture work.
Labs that study senescence rarely work with a single compound. Many of the same suppliers also carry cjc 1295 10mg, a 2x blend tesamorelin 10mg ipamorelin 5mg, and dsip 10mg for unrelated research lines. Those peptides act on entirely different pathways, so their results are not comparable to FOXO4-DRI.
How FOXO4-DRI Compares With Other Senolytics
| Compound | Primary mechanism | Typical research format | Notes |
|---|---|---|---|
| FOXO4-DRI | Disrupts FOXO4–p53 binding | Lyophilized 10mg vial | Peptide; senescent-cell apoptosis shown in mice |
| Dasatinib + Quercetin | Multiple kinase and flavonoid pathways | Oral, milligram scale | Most-studied senolytic combination in human trials |
| Navitoclax (ABT-263) | BCL-2 family inhibition | Oral | Platelet toxicity limits clinical use |
| Fisetin | Flavonoid, PI3K/AKT signaling | Oral | Widely sold as a supplement |
What the Published Research Actually Shows
The landmark study came from researchers at Erasmus University Medical Center in 2017. In that work, FOXO4-DRI restored fitness and fur density in fast-aging mice and improved several markers in naturally aged animals.
Important context: nearly all published data comes from cell cultures and rodent models. No controlled human trials of FOXO4-DRI have been published, so human safety and effectiveness remain unknown.
- Animal results do not automatically translate to people.
- Peptide half-life, delivery route, and dose all shape outcomes.
- Independent replication in human subjects is still missing.
Safety and Legal Status
FOXO4-DRI is sold as a research chemical, not a drug or dietary supplement. In the United States, the FDA has not approved it for any human indication, and marketing it as a treatment is not legal.
Anyone considering self-administration should speak with a licensed healthcare professional first. Senolytics influence cell-cycle regulation and immune signaling, and the unknown risks are real.
Searchers researching adjacent compounds often land in different corners of the peptide world. A search for where to buy bpc-157 and tb-500 points to tissue-repair research, while someone typing how does igf 1 lr3 work is exploring growth-factor signaling. FOXO4-DRI sits in the aging and senescence category, not in either of those areas.
Handling and Storage Basics
Lyophilized FOXO4-DRI stays stable for long periods when kept cold and dry. Once reconstituted, most peptides degrade faster and should be refrigerated and used within the window set by the lab protocol.
- Avoid repeated freeze-thaw cycles.
- Keep vials away from light and moisture.
- Use sterile technique during reconstitution.
- Record lot numbers and reconstitution dates.
Bottom Line
FOXO4-DRI 10mg is a research peptide with striking mouse data and no human trial data. It is a legitimate laboratory tool for studying cellular senescence, and it is not a proven anti-aging treatment. Anyone evaluating it for personal use should treat marketing claims with skepticism and consult a qualified clinician.
Frequently Asked Questions
What is FOXO4-DRI 10mg used for?
FOXO4-DRI 10mg is used in laboratory research on cellular senescence. Scientists use it to selectively trigger apoptosis in senescent cells by disrupting the FOXO4–p53 interaction. It has no approved medical use and is not intended for human consumption.
Is FOXO4-DRI legal to buy in the United States?
FOXO4-DRI is sold as a research chemical, which is legal for laboratory use in most states. It is not FDA-approved as a drug or dietary supplement, and selling it as a treatment for any condition is illegal. Buyers should confirm that the seller provides a third-party certificate of analysis.
Has FOXO4-DRI been tested in humans?
No published controlled human trials of FOXO4-DRI exist. The most-cited evidence comes from a 2017 mouse study in which the peptide improved fitness and fur density in aged animals. Human safety, dosing, and effectiveness remain unknown.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.